nodes	percent_of_prediction	percent_of_DWPC	metapath
Tobramycin—Lacrimation—Epirubicin—liver cancer	0.00595	0.00595	CcSEcCtD
Tobramycin—Local reaction—Doxorubicin—liver cancer	0.00585	0.00585	CcSEcCtD
Tobramycin—Transaminases increased—Epirubicin—liver cancer	0.00575	0.00575	CcSEcCtD
Tobramycin—Serum creatinine increased—Epirubicin—liver cancer	0.00569	0.00569	CcSEcCtD
Tobramycin—Hypophosphataemia—Doxorubicin—liver cancer	0.00557	0.00557	CcSEcCtD
Tobramycin—Hypomagnesaemia—Epirubicin—liver cancer	0.00551	0.00551	CcSEcCtD
Tobramycin—Lacrimation—Doxorubicin—liver cancer	0.00551	0.00551	CcSEcCtD
Tobramycin—Keratitis—Epirubicin—liver cancer	0.00539	0.00539	CcSEcCtD
Tobramycin—Weight decreased—Sorafenib—liver cancer	0.00537	0.00537	CcSEcCtD
Tobramycin—Transaminases increased—Doxorubicin—liver cancer	0.00532	0.00532	CcSEcCtD
Tobramycin—Infestation NOS—Sorafenib—liver cancer	0.0053	0.0053	CcSEcCtD
Tobramycin—Infestation—Sorafenib—liver cancer	0.0053	0.0053	CcSEcCtD
Tobramycin—Serum creatinine increased—Doxorubicin—liver cancer	0.00526	0.00526	CcSEcCtD
Tobramycin—Renal failure—Sorafenib—liver cancer	0.00521	0.00521	CcSEcCtD
Tobramycin—Neuropathy peripheral—Sorafenib—liver cancer	0.00519	0.00519	CcSEcCtD
Tobramycin—Stomatitis—Sorafenib—liver cancer	0.00516	0.00516	CcSEcCtD
Tobramycin—Hypomagnesaemia—Doxorubicin—liver cancer	0.0051	0.0051	CcSEcCtD
Tobramycin—Hyperventilation—Epirubicin—liver cancer	0.00508	0.00508	CcSEcCtD
Tobramycin—Epistaxis—Sorafenib—liver cancer	0.005	0.005	CcSEcCtD
Tobramycin—Keratitis—Doxorubicin—liver cancer	0.00499	0.00499	CcSEcCtD
Tobramycin—Lung disorder—Epirubicin—liver cancer	0.00494	0.00494	CcSEcCtD
Tobramycin—Laryngitis—Epirubicin—liver cancer	0.00485	0.00485	CcSEcCtD
Tobramycin—Haemoptysis—Epirubicin—liver cancer	0.00473	0.00473	CcSEcCtD
Tobramycin—Hyperventilation—Doxorubicin—liver cancer	0.0047	0.0047	CcSEcCtD
Tobramycin—Urinary tract disorder—Sorafenib—liver cancer	0.00469	0.00469	CcSEcCtD
Tobramycin—Connective tissue disorder—Sorafenib—liver cancer	0.00467	0.00467	CcSEcCtD
Tobramycin—Urethral disorder—Sorafenib—liver cancer	0.00466	0.00466	CcSEcCtD
Tobramycin—Lung disorder—Doxorubicin—liver cancer	0.00457	0.00457	CcSEcCtD
Tobramycin—Laryngitis—Doxorubicin—liver cancer	0.00449	0.00449	CcSEcCtD
Tobramycin—Tinnitus—Sorafenib—liver cancer	0.00443	0.00443	CcSEcCtD
Tobramycin—Haemoptysis—Doxorubicin—liver cancer	0.00437	0.00437	CcSEcCtD
Tobramycin—Stinging—Epirubicin—liver cancer	0.00432	0.00432	CcSEcCtD
Tobramycin—Angiopathy—Sorafenib—liver cancer	0.00431	0.00431	CcSEcCtD
Tobramycin—Immune system disorder—Sorafenib—liver cancer	0.00429	0.00429	CcSEcCtD
Tobramycin—Injection site pain—Epirubicin—liver cancer	0.00429	0.00429	CcSEcCtD
Tobramycin—Mediastinal disorder—Sorafenib—liver cancer	0.00428	0.00428	CcSEcCtD
Tobramycin—Dysphonia—Epirubicin—liver cancer	0.00425	0.00425	CcSEcCtD
Tobramycin—Erythema—Sorafenib—liver cancer	0.00414	0.00414	CcSEcCtD
Tobramycin—Delirium—Epirubicin—liver cancer	0.00407	0.00407	CcSEcCtD
Tobramycin—Dysgeusia—Sorafenib—liver cancer	0.00405	0.00405	CcSEcCtD
Tobramycin—Stinging—Doxorubicin—liver cancer	0.004	0.004	CcSEcCtD
Tobramycin—Injection site pain—Doxorubicin—liver cancer	0.00397	0.00397	CcSEcCtD
Tobramycin—Dysphonia—Doxorubicin—liver cancer	0.00393	0.00393	CcSEcCtD
Tobramycin—Bone disorder—Epirubicin—liver cancer	0.00387	0.00387	CcSEcCtD
Tobramycin—Anaemia—Sorafenib—liver cancer	0.00383	0.00383	CcSEcCtD
Tobramycin—Cough increased—Epirubicin—liver cancer	0.00382	0.00382	CcSEcCtD
Tobramycin—Hypocalcaemia—Epirubicin—liver cancer	0.00382	0.00382	CcSEcCtD
Tobramycin—Lacrimation increased—Epirubicin—liver cancer	0.0038	0.0038	CcSEcCtD
Tobramycin—Oliguria—Epirubicin—liver cancer	0.0038	0.0038	CcSEcCtD
Tobramycin—Angioedema—Sorafenib—liver cancer	0.00378	0.00378	CcSEcCtD
Tobramycin—Delirium—Doxorubicin—liver cancer	0.00376	0.00376	CcSEcCtD
Tobramycin—Leukopenia—Sorafenib—liver cancer	0.0037	0.0037	CcSEcCtD
Tobramycin—Blood bilirubin increased—Epirubicin—liver cancer	0.0037	0.0037	CcSEcCtD
Tobramycin—Creatinine increased—Epirubicin—liver cancer	0.00368	0.00368	CcSEcCtD
Tobramycin—Cough—Sorafenib—liver cancer	0.00361	0.00361	CcSEcCtD
Tobramycin—Bone disorder—Doxorubicin—liver cancer	0.00358	0.00358	CcSEcCtD
Tobramycin—Hypocalcaemia—Doxorubicin—liver cancer	0.00354	0.00354	CcSEcCtD
Tobramycin—Cough increased—Doxorubicin—liver cancer	0.00354	0.00354	CcSEcCtD
Tobramycin—Myalgia—Sorafenib—liver cancer	0.00352	0.00352	CcSEcCtD
Tobramycin—Oliguria—Doxorubicin—liver cancer	0.00351	0.00351	CcSEcCtD
Tobramycin—Lacrimation increased—Doxorubicin—liver cancer	0.00351	0.00351	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.0035	0.0035	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Epirubicin—liver cancer	0.0035	0.0035	CcSEcCtD
Tobramycin—Blood bilirubin increased—Doxorubicin—liver cancer	0.00342	0.00342	CcSEcCtD
Tobramycin—Creatinine increased—Doxorubicin—liver cancer	0.0034	0.0034	CcSEcCtD
Tobramycin—Anaphylactic shock—Sorafenib—liver cancer	0.00338	0.00338	CcSEcCtD
Tobramycin—Nervous system disorder—Sorafenib—liver cancer	0.00331	0.00331	CcSEcCtD
Tobramycin—Thrombocytopenia—Sorafenib—liver cancer	0.00331	0.00331	CcSEcCtD
Tobramycin—Skin disorder—Sorafenib—liver cancer	0.00328	0.00328	CcSEcCtD
Tobramycin—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.00324	0.00324	CcSEcCtD
Tobramycin—Dry eye—Epirubicin—liver cancer	0.00323	0.00323	CcSEcCtD
Tobramycin—Anorexia—Sorafenib—liver cancer	0.00322	0.00322	CcSEcCtD
Tobramycin—Rash maculo-papular—Epirubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00308	0.00308	CcSEcCtD
Tobramycin—Dyspnoea—Sorafenib—liver cancer	0.00301	0.00301	CcSEcCtD
Tobramycin—Dry eye—Doxorubicin—liver cancer	0.00299	0.00299	CcSEcCtD
Tobramycin—Rash maculo-papular—Doxorubicin—liver cancer	0.00294	0.00294	CcSEcCtD
Tobramycin—Decreased appetite—Sorafenib—liver cancer	0.00294	0.00294	CcSEcCtD
Tobramycin—Thrombophlebitis—Epirubicin—liver cancer	0.00293	0.00293	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00292	0.00292	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Sorafenib—liver cancer	0.00292	0.00292	CcSEcCtD
Tobramycin—Pain—Sorafenib—liver cancer	0.00289	0.00289	CcSEcCtD
Tobramycin—Eye pain—Epirubicin—liver cancer	0.00281	0.00281	CcSEcCtD
Tobramycin—Gastrointestinal pain—Sorafenib—liver cancer	0.00276	0.00276	CcSEcCtD
Tobramycin—Renal failure acute—Epirubicin—liver cancer	0.00275	0.00275	CcSEcCtD
Tobramycin—Thrombophlebitis—Doxorubicin—liver cancer	0.00271	0.00271	CcSEcCtD
Tobramycin—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.0027	0.0027	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Epirubicin—liver cancer	0.00269	0.00269	CcSEcCtD
Tobramycin—Urticaria—Sorafenib—liver cancer	0.00268	0.00268	CcSEcCtD
Tobramycin—Abdominal pain—Sorafenib—liver cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Body temperature increased—Sorafenib—liver cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Renal impairment—Epirubicin—liver cancer	0.00267	0.00267	CcSEcCtD
Tobramycin—Eye pain—Doxorubicin—liver cancer	0.0026	0.0026	CcSEcCtD
Tobramycin—Lethargy—Epirubicin—liver cancer	0.00259	0.00259	CcSEcCtD
Tobramycin—Renal failure acute—Doxorubicin—liver cancer	0.00255	0.00255	CcSEcCtD
Tobramycin—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00249	0.00249	CcSEcCtD
Tobramycin—Hypersensitivity—Sorafenib—liver cancer	0.00249	0.00249	CcSEcCtD
Tobramycin—Renal impairment—Doxorubicin—liver cancer	0.00247	0.00247	CcSEcCtD
Tobramycin—Asthenia—Sorafenib—liver cancer	0.00242	0.00242	CcSEcCtD
Tobramycin—Lethargy—Doxorubicin—liver cancer	0.0024	0.0024	CcSEcCtD
Tobramycin—Pruritus—Sorafenib—liver cancer	0.00239	0.00239	CcSEcCtD
Tobramycin—Blood creatinine increased—Epirubicin—liver cancer	0.00238	0.00238	CcSEcCtD
Tobramycin—Dehydration—Epirubicin—liver cancer	0.00236	0.00236	CcSEcCtD
Tobramycin—Dry skin—Epirubicin—liver cancer	0.00233	0.00233	CcSEcCtD
Tobramycin—Hypokalaemia—Epirubicin—liver cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Diarrhoea—Sorafenib—liver cancer	0.00231	0.00231	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00229	0.00229	CcSEcCtD
Tobramycin—Muscular weakness—Epirubicin—liver cancer	0.00224	0.00224	CcSEcCtD
Tobramycin—Dizziness—Sorafenib—liver cancer	0.00223	0.00223	CcSEcCtD
Tobramycin—Blood creatinine increased—Doxorubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Tobramycin—Asthma—Epirubicin—liver cancer	0.0022	0.0022	CcSEcCtD
Tobramycin—Dehydration—Doxorubicin—liver cancer	0.00219	0.00219	CcSEcCtD
Tobramycin—Eosinophilia—Epirubicin—liver cancer	0.00217	0.00217	CcSEcCtD
Tobramycin—Dry skin—Doxorubicin—liver cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Vomiting—Sorafenib—liver cancer	0.00215	0.00215	CcSEcCtD
Tobramycin—Hypokalaemia—Doxorubicin—liver cancer	0.00214	0.00214	CcSEcCtD
Tobramycin—Rash—Sorafenib—liver cancer	0.00213	0.00213	CcSEcCtD
Tobramycin—Dermatitis—Sorafenib—liver cancer	0.00213	0.00213	CcSEcCtD
Tobramycin—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00212	0.00212	CcSEcCtD
Tobramycin—Headache—Sorafenib—liver cancer	0.00212	0.00212	CcSEcCtD
Tobramycin—Bronchitis—Epirubicin—liver cancer	0.00211	0.00211	CcSEcCtD
Tobramycin—Muscular weakness—Doxorubicin—liver cancer	0.00207	0.00207	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Epirubicin—liver cancer	0.00204	0.00204	CcSEcCtD
Tobramycin—Asthma—Doxorubicin—liver cancer	0.00203	0.00203	CcSEcCtD
Tobramycin—Eosinophilia—Doxorubicin—liver cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Nausea—Sorafenib—liver cancer	0.00201	0.00201	CcSEcCtD
Tobramycin—Weight decreased—Epirubicin—liver cancer	0.00199	0.00199	CcSEcCtD
Tobramycin—Infestation NOS—Epirubicin—liver cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Infestation—Epirubicin—liver cancer	0.00196	0.00196	CcSEcCtD
Tobramycin—Bronchitis—Doxorubicin—liver cancer	0.00195	0.00195	CcSEcCtD
Tobramycin—Renal failure—Epirubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Tobramycin—Neuropathy peripheral—Epirubicin—liver cancer	0.00192	0.00192	CcSEcCtD
Tobramycin—Stomatitis—Epirubicin—liver cancer	0.00191	0.00191	CcSEcCtD
Tobramycin—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00189	0.00189	CcSEcCtD
Tobramycin—Epistaxis—Epirubicin—liver cancer	0.00185	0.00185	CcSEcCtD
Tobramycin—Weight decreased—Doxorubicin—liver cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Sinusitis—Epirubicin—liver cancer	0.00184	0.00184	CcSEcCtD
Tobramycin—Agranulocytosis—Epirubicin—liver cancer	0.00183	0.00183	CcSEcCtD
Tobramycin—Infestation NOS—Doxorubicin—liver cancer	0.00181	0.00181	CcSEcCtD
Tobramycin—Infestation—Doxorubicin—liver cancer	0.00181	0.00181	CcSEcCtD
Tobramycin—Renal failure—Doxorubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Neuropathy peripheral—Doxorubicin—liver cancer	0.00178	0.00178	CcSEcCtD
Tobramycin—Stomatitis—Doxorubicin—liver cancer	0.00177	0.00177	CcSEcCtD
Tobramycin—Rhinitis—Epirubicin—liver cancer	0.00176	0.00176	CcSEcCtD
Tobramycin—Pharyngitis—Epirubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Urinary tract disorder—Epirubicin—liver cancer	0.00174	0.00174	CcSEcCtD
Tobramycin—Connective tissue disorder—Epirubicin—liver cancer	0.00173	0.00173	CcSEcCtD
Tobramycin—Urethral disorder—Epirubicin—liver cancer	0.00172	0.00172	CcSEcCtD
Tobramycin—Epistaxis—Doxorubicin—liver cancer	0.00171	0.00171	CcSEcCtD
Tobramycin—Sinusitis—Doxorubicin—liver cancer	0.0017	0.0017	CcSEcCtD
Tobramycin—Visual impairment—Epirubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Agranulocytosis—Doxorubicin—liver cancer	0.00169	0.00169	CcSEcCtD
Tobramycin—Eye disorder—Epirubicin—liver cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Tinnitus—Epirubicin—liver cancer	0.00164	0.00164	CcSEcCtD
Tobramycin—Rhinitis—Doxorubicin—liver cancer	0.00163	0.00163	CcSEcCtD
Tobramycin—Pharyngitis—Doxorubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Urinary tract disorder—Doxorubicin—liver cancer	0.00161	0.00161	CcSEcCtD
Tobramycin—Connective tissue disorder—Doxorubicin—liver cancer	0.0016	0.0016	CcSEcCtD
Tobramycin—Angiopathy—Epirubicin—liver cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Urethral disorder—Doxorubicin—liver cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Immune system disorder—Epirubicin—liver cancer	0.00159	0.00159	CcSEcCtD
Tobramycin—Mediastinal disorder—Epirubicin—liver cancer	0.00158	0.00158	CcSEcCtD
Tobramycin—Visual impairment—Doxorubicin—liver cancer	0.00157	0.00157	CcSEcCtD
Tobramycin—Erythema—Epirubicin—liver cancer	0.00153	0.00153	CcSEcCtD
Tobramycin—Eye disorder—Doxorubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Tinnitus—Doxorubicin—liver cancer	0.00152	0.00152	CcSEcCtD
Tobramycin—Dysgeusia—Epirubicin—liver cancer	0.0015	0.0015	CcSEcCtD
Tobramycin—Back pain—Epirubicin—liver cancer	0.00148	0.00148	CcSEcCtD
Tobramycin—Angiopathy—Doxorubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Immune system disorder—Doxorubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Mediastinal disorder—Doxorubicin—liver cancer	0.00147	0.00147	CcSEcCtD
Tobramycin—Vision blurred—Epirubicin—liver cancer	0.00144	0.00144	CcSEcCtD
Tobramycin—Ill-defined disorder—Epirubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Erythema—Doxorubicin—liver cancer	0.00142	0.00142	CcSEcCtD
Tobramycin—Anaemia—Epirubicin—liver cancer	0.00141	0.00141	CcSEcCtD
Tobramycin—Dysgeusia—Doxorubicin—liver cancer	0.00139	0.00139	CcSEcCtD
Tobramycin—Malaise—Epirubicin—liver cancer	0.00138	0.00138	CcSEcCtD
Tobramycin—Vertigo—Epirubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Leukopenia—Epirubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Back pain—Doxorubicin—liver cancer	0.00137	0.00137	CcSEcCtD
Tobramycin—Cough—Epirubicin—liver cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Vision blurred—Doxorubicin—liver cancer	0.00133	0.00133	CcSEcCtD
Tobramycin—Ill-defined disorder—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Anaemia—Doxorubicin—liver cancer	0.00131	0.00131	CcSEcCtD
Tobramycin—Myalgia—Epirubicin—liver cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Chest pain—Epirubicin—liver cancer	0.0013	0.0013	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Discomfort—Epirubicin—liver cancer	0.00129	0.00129	CcSEcCtD
Tobramycin—Malaise—Doxorubicin—liver cancer	0.00128	0.00128	CcSEcCtD
Tobramycin—Vertigo—Doxorubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Leukopenia—Doxorubicin—liver cancer	0.00127	0.00127	CcSEcCtD
Tobramycin—Confusional state—Epirubicin—liver cancer	0.00126	0.00126	CcSEcCtD
Tobramycin—Anaphylactic shock—Epirubicin—liver cancer	0.00125	0.00125	CcSEcCtD
Tobramycin—Cough—Doxorubicin—liver cancer	0.00123	0.00123	CcSEcCtD
Tobramycin—Nervous system disorder—Epirubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Thrombocytopenia—Epirubicin—liver cancer	0.00122	0.00122	CcSEcCtD
Tobramycin—Skin disorder—Epirubicin—liver cancer	0.00121	0.00121	CcSEcCtD
Tobramycin—Chest pain—Doxorubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Myalgia—Doxorubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.0012	0.0012	CcSEcCtD
Tobramycin—Discomfort—Doxorubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Anorexia—Epirubicin—liver cancer	0.00119	0.00119	CcSEcCtD
Tobramycin—Confusional state—Doxorubicin—liver cancer	0.00116	0.00116	CcSEcCtD
Tobramycin—Anaphylactic shock—Doxorubicin—liver cancer	0.00115	0.00115	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00114	0.00114	CcSEcCtD
Tobramycin—Nervous system disorder—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Thrombocytopenia—Doxorubicin—liver cancer	0.00113	0.00113	CcSEcCtD
Tobramycin—Skin disorder—Doxorubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Paraesthesia—Epirubicin—liver cancer	0.00112	0.00112	CcSEcCtD
Tobramycin—Dyspnoea—Epirubicin—liver cancer	0.00111	0.00111	CcSEcCtD
Tobramycin—Anorexia—Doxorubicin—liver cancer	0.0011	0.0011	CcSEcCtD
Tobramycin—Decreased appetite—Epirubicin—liver cancer	0.00109	0.00109	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Epirubicin—liver cancer	0.00108	0.00108	CcSEcCtD
Tobramycin—Pain—Epirubicin—liver cancer	0.00107	0.00107	CcSEcCtD
Tobramycin—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00105	0.00105	CcSEcCtD
Tobramycin—Paraesthesia—Doxorubicin—liver cancer	0.00104	0.00104	CcSEcCtD
Tobramycin—Dyspnoea—Doxorubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Tobramycin—Feeling abnormal—Epirubicin—liver cancer	0.00103	0.00103	CcSEcCtD
Tobramycin—Gastrointestinal pain—Epirubicin—liver cancer	0.00102	0.00102	CcSEcCtD
Tobramycin—Decreased appetite—Doxorubicin—liver cancer	0.001	0.001	CcSEcCtD
Tobramycin—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000997	0.000997	CcSEcCtD
Tobramycin—Urticaria—Epirubicin—liver cancer	0.000992	0.000992	CcSEcCtD
Tobramycin—Pain—Doxorubicin—liver cancer	0.000988	0.000988	CcSEcCtD
Tobramycin—Abdominal pain—Epirubicin—liver cancer	0.000987	0.000987	CcSEcCtD
Tobramycin—Body temperature increased—Epirubicin—liver cancer	0.000987	0.000987	CcSEcCtD
Tobramycin—Feeling abnormal—Doxorubicin—liver cancer	0.000952	0.000952	CcSEcCtD
Tobramycin—Gastrointestinal pain—Doxorubicin—liver cancer	0.000944	0.000944	CcSEcCtD
Tobramycin—Hypersensitivity—Epirubicin—liver cancer	0.00092	0.00092	CcSEcCtD
Tobramycin—Urticaria—Doxorubicin—liver cancer	0.000918	0.000918	CcSEcCtD
Tobramycin—Body temperature increased—Doxorubicin—liver cancer	0.000913	0.000913	CcSEcCtD
Tobramycin—Abdominal pain—Doxorubicin—liver cancer	0.000913	0.000913	CcSEcCtD
Tobramycin—Asthenia—Epirubicin—liver cancer	0.000896	0.000896	CcSEcCtD
Tobramycin—Pruritus—Epirubicin—liver cancer	0.000883	0.000883	CcSEcCtD
Tobramycin—Diarrhoea—Epirubicin—liver cancer	0.000854	0.000854	CcSEcCtD
Tobramycin—Hypersensitivity—Doxorubicin—liver cancer	0.000851	0.000851	CcSEcCtD
Tobramycin—Asthenia—Doxorubicin—liver cancer	0.000829	0.000829	CcSEcCtD
Tobramycin—Dizziness—Epirubicin—liver cancer	0.000825	0.000825	CcSEcCtD
Tobramycin—Pruritus—Doxorubicin—liver cancer	0.000817	0.000817	CcSEcCtD
Tobramycin—Vomiting—Epirubicin—liver cancer	0.000794	0.000794	CcSEcCtD
Tobramycin—Diarrhoea—Doxorubicin—liver cancer	0.00079	0.00079	CcSEcCtD
Tobramycin—Rash—Epirubicin—liver cancer	0.000787	0.000787	CcSEcCtD
Tobramycin—Dermatitis—Epirubicin—liver cancer	0.000786	0.000786	CcSEcCtD
Tobramycin—Headache—Epirubicin—liver cancer	0.000782	0.000782	CcSEcCtD
Tobramycin—Dizziness—Doxorubicin—liver cancer	0.000764	0.000764	CcSEcCtD
Tobramycin—Nausea—Epirubicin—liver cancer	0.000741	0.000741	CcSEcCtD
Tobramycin—Vomiting—Doxorubicin—liver cancer	0.000734	0.000734	CcSEcCtD
Tobramycin—Rash—Doxorubicin—liver cancer	0.000728	0.000728	CcSEcCtD
Tobramycin—Dermatitis—Doxorubicin—liver cancer	0.000728	0.000728	CcSEcCtD
Tobramycin—Headache—Doxorubicin—liver cancer	0.000724	0.000724	CcSEcCtD
Tobramycin—Nausea—Doxorubicin—liver cancer	0.000686	0.000686	CcSEcCtD
